论文部分内容阅读
目的探讨孕中期孕妇产前筛查的临床应用价值。方法对2010年1月至2011年7月在商丘市妇幼保健院妇产科进行甲胎蛋白(AFP)、游离β-人绒毛膜促性腺激素(Free-β-hCG)及抑制素A(inhibin-A)三项目产前检查,对高风险率孕妇进行羊水细胞染色体检查。结果 4152例孕中期孕妇产前筛查显示52例(1.25%)为唐氏综合征高风险孕妇,49例(1.18%)为18-三体综合征高风险孕妇,67例(1.61%)为神经管缺陷高风险孕妇。先天缺陷高风险孕妇共168例,产前筛查阳性率达4.05%。羊水细胞染色体核型分析显示11例(6.55%)核型异常。结论 AFP、Free-β-hCG与in-hibin-A三项筛查项目联合可以有效对先天缺陷胎儿进行产前筛查。在筛查过程中,三项检测结果可以相互印证,提高阳性检出率,同时有效降低筛查的假阳性率。
Objective To explore the clinical value of prenatal screening in the second trimester of pregnancy. Methods AFP, Free-β-hCG and inhibin A were isolated from obstetrics and gynecology department of Shangqiu MCH hospital from January 2010 to July 2011, -A) three items of prenatal care, high risk pregnant women for amniotic fluid chromosome examination. Results Prenatal screening of 4152 pregnant women at the second trimester showed that 52 (1.25%) pregnant women with high risk of Down’s syndrome and 49 (1.18%) pregnant women with high risk of trisomy 18, 67 (1.61%) were Neural tube defects in high-risk pregnant women. 168 cases of high risk of congenital defects in pregnant women, prenatal screening positive rate of 4.05%. Amniotic fluid chromosome karyotype analysis showed karyotype abnormalities in 11 cases (6.55%). Conclusion The combination of AFP, Free-β-hCG and in-hibin-A screening can effectively screen prenatal fetuses with congenital defects. During the screening process, the three test results can confirm each other to improve the positive detection rate, while effectively reducing the false positive rate of screening.